183 related articles for article (PubMed ID: 36907523)
1. A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer.
Yoo HB; Moon JW; Kim HR; Lee HS; Miyabayashi K; Park CH; Ge S; Zhang A; Tae YK; Sub Y; Park HW; Gee HY; Notta F; Tuveson DA; Bang S; Kim MY; Roe JS
Gastroenterology; 2023 Jul; 165(1):133-148.e17. PubMed ID: 36907523
[TBL] [Abstract][Full Text] [Related]
2. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis.
Roe JS; Hwang CI; Somerville TDD; Milazzo JP; Lee EJ; Da Silva B; Maiorino L; Tiriac H; Young CM; Miyabayashi K; Filippini D; Creighton B; Burkhart RA; Buscaglia JM; Kim EJ; Grem JL; Lazenby AJ; Grunkemeyer JA; Hollingsworth MA; Grandgenett PM; Egeblad M; Park Y; Tuveson DA; Vakoc CR
Cell; 2017 Aug; 170(5):875-888.e20. PubMed ID: 28757253
[TBL] [Abstract][Full Text] [Related]
3. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.
Puleo F; Nicolle R; Blum Y; Cros J; Marisa L; Demetter P; Quertinmont E; Svrcek M; Elarouci N; Iovanna J; Franchimont D; Verset L; Galdon MG; Devière J; de Reyniès A; Laurent-Puig P; Van Laethem JL; Bachet JB; Maréchal R
Gastroenterology; 2018 Dec; 155(6):1999-2013.e3. PubMed ID: 30165049
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer.
Adams CR; Htwe HH; Marsh T; Wang AL; Montoya ML; Subbaraj L; Tward AD; Bardeesy N; Perera RM
Elife; 2019 May; 8():. PubMed ID: 31134896
[TBL] [Abstract][Full Text] [Related]
5. TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma.
Somerville TDD; Xu Y; Miyabayashi K; Tiriac H; Cleary CR; Maia-Silva D; Milazzo JP; Tuveson DA; Vakoc CR
Cell Rep; 2018 Nov; 25(7):1741-1755.e7. PubMed ID: 30428345
[TBL] [Abstract][Full Text] [Related]
6. A mucus production programme promotes classical pancreatic ductal adenocarcinoma.
Tonelli C; Yordanov GN; Hao Y; Deschênes A; Hinds J; Belleau P; Klingbeil O; Brosnan E; Doshi A; Park Y; Hruban RH; Vakoc CR; Dobin A; Preall J; Tuveson DA
Gut; 2024 May; 73(6):941-954. PubMed ID: 38262672
[TBL] [Abstract][Full Text] [Related]
7. Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma.
Wang X; Kutschat AP; Aggrey-Fynn J; Hamdan FH; Graham RP; Wixom AQ; Souto Y; Ladigan-Badura S; Yonkus JA; Abdelrahman AM; Alva-Ruiz R; Gaedcke J; Ströbel P; Kosinsky RL; Wegwitz F; Hermann P; Truty MJ; Siveke JT; Hahn SA; Hessmann E; Johnsen SA; Najafova Z
Mol Cancer Res; 2023 Sep; 21(9):881-891. PubMed ID: 37279184
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Alterations in Pancreatic Cancer Metastasis.
Wang SS; Xu J; Ji KY; Hwang CI
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439749
[TBL] [Abstract][Full Text] [Related]
9. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of
Patil S; Steuber B; Kopp W; Kari V; Urbach L; Wang X; Küffer S; Bohnenberger H; Spyropoulou D; Zhang Z; Versemann L; Bösherz MS; Brunner M; Gaedcke J; Ströbel P; Zhang JS; Neesse A; Ellenrieder V; Singh SK; Johnsen SA; Hessmann E
Cancer Res; 2020 Nov; 80(21):4620-4632. PubMed ID: 32907838
[TBL] [Abstract][Full Text] [Related]
10. SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer.
Ohara Y; Tang W; Liu H; Yang S; Dorsey TH; Cawley H; Moreno P; Chari R; Guest MR; Azizian A; Gaedcke J; Ghadimi M; Hanna N; Ambs S; Hussain SP
Cell Rep; 2023 Dec; 42(12):113434. PubMed ID: 37980563
[TBL] [Abstract][Full Text] [Related]
11. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.
Topham JT; Karasinska JM; Lee MKC; Csizmok V; Williamson LM; Jang GH; Denroche RE; Tsang ES; Kalloger SE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Notta F; Loree JM; Wilson JM; Bathe O; Tang PA; Goodwin R; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Renouf DJ; Schaeffer DF
Clin Cancer Res; 2021 Jan; 27(1):150-157. PubMed ID: 33051307
[TBL] [Abstract][Full Text] [Related]
12. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
13. ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer.
Somerville TDD; Xu Y; Wu XS; Maia-Silva D; Hur SK; de Almeida LMN; Preall JB; Koo PK; Vakoc CR
Proc Natl Acad Sci U S A; 2020 May; 117(21):11471-11482. PubMed ID: 32385160
[TBL] [Abstract][Full Text] [Related]
14. The basic helix-loop-helix transcription factor E47 reprograms human pancreatic cancer cells to a quiescent acinar state with reduced tumorigenic potential.
Kim S; Lahmy R; Riha C; Yang C; Jakubison BL; van Niekerk J; Staub C; Wu Y; Gates K; Dong DS; Konieczny SF; Itkin-Ansari P
Pancreas; 2015 Jul; 44(5):718-27. PubMed ID: 25894862
[TBL] [Abstract][Full Text] [Related]
15. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.
Seifert L; Werba G; Tiwari S; Giao Ly NN; Alothman S; Alqunaibit D; Avanzi A; Barilla R; Daley D; Greco SH; Torres-Hernandez A; Pergamo M; Ochi A; Zambirinis CP; Pansari M; Rendon M; Tippens D; Hundeyin M; Mani VR; Hajdu C; Engle D; Miller G
Nature; 2016 Apr; 532(7598):245-9. PubMed ID: 27049944
[TBL] [Abstract][Full Text] [Related]
16. Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution.
Hosein AN; Huang H; Wang Z; Parmar K; Du W; Huang J; Maitra A; Olson E; Verma U; Brekken RA
JCI Insight; 2019 Jul; 5(16):. PubMed ID: 31335328
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma.
Masugi Y; Yamazaki K; Emoto K; Effendi K; Tsujikawa H; Kitago M; Itano O; Kitagawa Y; Sakamoto M
Lab Invest; 2015 Mar; 95(3):308-19. PubMed ID: 25599535
[TBL] [Abstract][Full Text] [Related]
18. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer.
Kloesch B; Ionasz V; Paliwal S; Hruschka N; Martinez de Villarreal J; Öllinger R; Mueller S; Dienes HP; Schindl M; Gruber ES; Stift J; Herndler-Brandstetter D; Lomberk GA; Seidler B; Saur D; Rad R; Urrutia RA; Real FX; Martinelli P
Gut; 2022 Apr; 71(4):766-777. PubMed ID: 33846140
[TBL] [Abstract][Full Text] [Related]
19. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression.
Fukuda A; Wang SC; Morris JP; Folias AE; Liou A; Kim GE; Akira S; Boucher KM; Firpo MA; Mulvihill SJ; Hebrok M
Cancer Cell; 2011 Apr; 19(4):441-55. PubMed ID: 21481787
[TBL] [Abstract][Full Text] [Related]
20. CD109 promotes the tumorigenic ability and metastatic motility of pancreatic ductal adenocarcinoma cells.
Hatsuzawa Y; Yamaguchi K; Takanashi T; Sato I; Tamai K; Mochizuki M; Iwai W; Wakui Y; Abue M; Yamamoto K; Yasuda J; Mizuma M; Unno M; Sugamura K
Pancreatology; 2020 Apr; 20(3):493-500. PubMed ID: 32007357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
